Logo image
Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and -haemolytic streptococci collected from western European countries in 2011
Journal article   Peer reviewed

Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and -haemolytic streptococci collected from western European countries in 2011

I. Morrissey, H. Seifert, R. Canton, P. Nordmann, S. Stefani, A. MacGowan, R. Janes and D. Knight
Journal of Antimicrobial Chemotherapy, Vol.68(1), pp.164-167
2013
url
Link to Published Version *Subscription may be requiredView

Abstract

Objectives To determine the activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci (VRE) and β-haemolytic streptococci recently isolated from acute bacterial skin and skin structure infections or bacteraemia in western Europe. Methods Forty-one centres in Spain (8), Italy (9), Germany (8), France (8) and the UK (8) submitted 866 isolates [204 methicillin-resistant Staphylococcus aureus (MRSA), 177 methicillin-resistant coagulase-negative staphylococci (MRCoNS), 101 VRE, 193 Streptococcus agalactiae and 191 Streptococcus pyogenes] that were collected during the first 6 months of 2011. These were re-identified and susceptibilities to oritavancin and comparators were determined. Results Oritavancin was very active against MRSA (MIC50/MIC90 0.03/0.06 mg/L), MRCoNS (0.06/0.12 mg/L), VRE (0.03/0.06 mg/L), S. agalactiae (0.03/0.06 mg/L) and S. pyogenes (0.06/0.25 mg/L). The highest oritavancin MIC observed was 0.25 mg/L (species were S. aureus, Staphylococcus epidermidis, Staphylococcus hominis, S. agalactiae, S. pyogenes and Enterococcus faecalis). Conclusions These data from recently collected Gram-positive bacteria in western Europe confirm the potent in vitro activity of oritavancin against a wide range of resistant MRSA, MRCoNS and VRE isolates, including ones resistant to newer agents.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Industry collaboration
Domestic collaboration
International collaboration
Citation topics
1 Clinical & Life Sciences
1.23 Antibiotics & Antimicrobials
1.23.173 MRSA and VRE
Web Of Science research areas
Infectious Diseases
Microbiology
Pharmacology & Pharmacy
ESI research areas
Pharmacology & Toxicology
Logo image